Companies Dominating the Companion Animal Drugs Landscape
- Agrolabo S.p.A.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Boehringer Ingelheim International GmbH
- Ceva Santé Animale
- Chanelle Pharma
- Dechra Pharmaceuticals PLC
- Elanco Animal Health Incorporated
- Endovac Animal Health
- HIPRA
- Indian Immunologicals Ltd.
- Merck & Co., Inc.
- Norbrook
- Symrise
- Vetoquinol
- Virbac
- Zoetis Inc.
- Akston
The current leading companies in the companion animal drugs market are focusing on integrating technological advancements to gain global recognition. They are developing connective platforms to bring innovation in this sector. In addition, advancements in technologies also ignite R&D, creating a scope for future development in this sector. For instance, in March 2024, Boehringer Ingelheim acquired Saiba Animal Health to incorporate the innovative technology platform of Saiba for accelerating its R&D on therapeutics. This acquisition will allow the global leader to access Saiba’s therapeutic vaccine approach to create an immune response, defending allergy, inflammation, and pain in pets. Such key players include:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of companion animal medicine is estimated at USD 24.87 billion.
Companion Animal Medicine Market size was over USD 22.98 billion in 2024 and is anticipated to cross USD 76.57 billion by 2037, witnessing more than 9.7% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is estimated to hold largest revenue share by 2037, owing to rising adoption of animals as a pet in the region.
The major players in the market include Bayer AG, Merck & Company, Inc., Elanco, Boehringer Ingelheim International GmbH, Virbac, Perrigo Company plc, Vetoquinol SA, Zoetis Inc., Ceva, Nutreco N.V., and others.
